WallStSmart

Definitive Healthcare Corp (DH)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 28507% more annual revenue ($66.57B vs $232.70M). MRK leads profitability with a 4.8% profit margin vs -72.3%. DH earns a higher WallStSmart Score of 37/100 (F).

DH

Hold

37

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 5/9Altman Z: -1.24

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHUndervalued (+76.2%)

Margin of Safety

+76.2%

Fair Value

$7.09

Current Price

$0.89

$6.20 discount

UndervaluedFair: $7.09Overvalued
MRKSignificantly Overvalued (-77.2%)

Margin of Safety

-77.2%

Fair Value

$83.04

Current Price

$150.91

$67.87 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DH1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

DH4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$112.08M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.153/10

Elevated debt levels

Return on EquityProfitability
-116.5%2/10

ROE of -116.5% — below average capital efficiency

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.9x4/10

Trading at 8.9x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : DH

The strongest argument for DH centers on Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : DH

The primary concerns for DH are EPS Growth, Market Cap, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

DH profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

DH carries more volatility with a beta of 1.40 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

DH scores higher overall (37/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Definitive Healthcare Corp

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Definitive Healthcare Corp (DH) is a leading provider of comprehensive data and analytics solutions designed specifically for the healthcare industry, catering to a diverse clientele that includes pharmaceutical companies, payers, and healthcare providers. By harnessing extensive datasets and cutting-edge real-time analytics, Definitive Healthcare enhances operational efficiencies and delivers critical strategic insights, ultimately improving patient outcomes. With a strong commitment to innovation, the company is well-positioned to capitalize on the growing demand for sophisticated healthcare analytics, thereby establishing itself as a pivotal player in the transformation of healthcare delivery.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?